Form 4: Gossamer Bio COO/CFO Bryan Giraudo Acquires 100,000 Shares of Common Stock

Bryan Giraudo, COO/CFO of Gossamer Bio, Inc., purchased 100,000 shares of common stock at a price of $0.5911 per share on June 18, 2024.

Summary

• On June 18, 2024, Bryan Giraudo, the COO/CFO of Gossamer Bio, Inc., acquired 100,000 shares of the company's common stock.
• The purchase price was $0.5911 per share.
• Following the transaction, Giraudo beneficially owns 480,010 shares indirectly through a family trust.
• A previous transaction on March 27, 2024, involving the sale of 6,430 shares at $1.1556 per share, was matchable under Section 16(b) of the Securities Exchange Act of 1934.
• Giraudo has agreed to pay Gossamer Bio $3,653.10, representing the profit realized from the short-swing transaction, less transaction costs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the insider purchase is a positive sign, the short-swing transaction and subsequent repayment are slightly negative, balancing the overall sentiment.

Positives

• The purchase of 100,000 shares by the COO/CFO could be interpreted as a sign of confidence in the company's future prospects.

Negatives

• The short-swing transaction requiring repayment of profits could be seen as a minor compliance oversight.

Risks

• The document does not explicitly mention any risks.
• However, insider transactions are always subject to scrutiny and potential legal challenges if not handled correctly.

Industry Context

Insider trading activity is closely monitored in the biotech industry, as it can provide insights into a company's prospects and management's confidence. Form 4 filings are a routine part of this monitoring process.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, as mandated by the SEC.
• The short-swing profit rule under Section 16(b) is a common regulatory consideration for corporate officers.
• Similar filings are made by executives at companies like Amgen, Gilead, and Biogen when they trade their company's stock.

Stakeholder Impact

• The insider purchase could positively influence shareholder sentiment.
• The repayment of short-swing profits ensures compliance with regulations.

Key Dates